Literature DB >> 2693516

Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.

D Papalia1, M Lunetta, M Di Mauro.   

Abstract

Recent studies suggest that opioid peptides may influence the secretion of pituitary gland hormones. Since obese patients often show impaired growth hormone (GH), prolactin (PRL) and cortisol responses to stimuli and raised beta endorphin levels, the opioid regulation of such hormone secretion could be different from that in normal weight subjects. In order to verify this hypothesis we studied the effect of iv naloxone, an opiate receptor antagonist, on GH, PRL and cortisol response to insulin-induced hypoglycemia in 9 obese female subjects. Seven normal weight females were used as control group. A control test using saline showed that the PRL and GH responses to insulin stress were impaired in obese subjects, whereas no difference was seen in the cortisol response. Naloxone did not modify the PRL and GH response but provoked a rise in the cortisol response in both obese and normal weight subjects. These findings suggest that while the opioid peptides do not play an important role in regulating the GH and PRL response to insulin hypoglycemia, they influence the cortisol response. In obese patients the impairment in GH and PRL response to stimuli cannot be related to alterations in opioid peptide regulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693516     DOI: 10.1007/BF03350058

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Effects of insulin-induced hypoglycemia on the plasma cortisol and growth-hormone levels in obese and diabetic persons.

Authors:  M Góth; J Gönczi
Journal:  Endokrinologie       Date:  1972-06

2.  Endocrine disturbances in childhood obesity: growth-hormone and cortisol response to insulin induced hypoglycemia.

Authors:  J Girard; M Stahl; P W Nars; J B Baumann
Journal:  Klin Wochenschr       Date:  1972-07-15

Review 3.  Brain peptides (first of two parts).

Authors:  D T Krieger; J B Martin
Journal:  N Engl J Med       Date:  1981-04-09       Impact factor: 91.245

4.  Endocrine effects of naloxone-induced opiate receptor blockade.

Authors:  J E Morley; N G Baranetsky; T D Wingert; H E Carlson; J M Hershman; S Melmed; S R Levin; K R Jamison; R Weitzman; R J Chang; A A Varner
Journal:  J Clin Endocrinol Metab       Date:  1980-02       Impact factor: 5.958

5.  Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

Authors:  G Plewe; U Schneider; U Krause; J Beyer
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

6.  The role of opioid peptides in the hormonal responses to acute exercise in man.

Authors:  A Grossman; P Bouloux; P Price; P L Drury; K S Lam; T Turner; J Thomas; G M Besser; J Sutton
Journal:  Clin Sci (Lond)       Date:  1984-11       Impact factor: 6.124

Review 7.  Endocrine actions of opioids.

Authors:  A Pfeiffer; A Herz
Journal:  Horm Metab Res       Date:  1984-08       Impact factor: 2.936

8.  beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland.

Authors:  R Guillemin; T Vargo; J Rossier; S Minick; N Ling; C Rivier; W Vale; F Bloom
Journal:  Science       Date:  1977-09-30       Impact factor: 47.728

9.  Impaired hypothalamic control of prolactin secretion in massive obesity.

Authors:  P G Kopelman; N White; T R Pilkington; S L Jeffcoate
Journal:  Lancet       Date:  1979-04-07       Impact factor: 79.321

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  1 in total

Review 1.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.